Wise · PloS one 2016 · randomized controlled trial · n=89

Lack of Effect of Oral Sulforaphane Administration on Nrf2 Expression in COPD: A Randomized, Double-Blind, Placebo Controlled Trial.

Cited 121 times in the scientific literature.

Level 2 - randomized trial

Phase 2 randomized, double-blind, placebo-controlled trial

PubMed 27832073 · doi:10.1371/journal.pone.0163716 · record verified 2026-08-30

What was done

A phase 2, parallel, double-blind, randomized, placebo-controlled trial evaluated oral sulforaphane in 89 patients meeting GOLD criteria for COPD across three US academic medical centers. Participants able to tolerate bronchoscopies were assigned (1:1:1) to placebo, 25 μmoles, or 150 μmoles of sulforaphane daily for four weeks. The primary outcome was change in Nrf2 target gene expression (NQO1, HO1, AKR1C1, AKR1C3) in alveolar macrophages and bronchial epithelial cells. Secondary outcomes included markers of oxidative stress, airway inflammation, and pulmonary function tests.

What was found

Sulforaphane was absorbed as confirmed by plasma metabolite levels and was well tolerated. Changes in Nrf2 target gene expression relative to baseline ranged from 0.79 to 1.45 across groups, with no consistent pattern and no statistically significant difference from baseline. Changes in airway inflammation measures and pulmonary function tests also showed no significant differences between the sulforaphane and placebo groups.

Why it matters

Despite strong preclinical evidence that sulforaphane stimulates antioxidant defenses via Nrf2, oral administration in COPD patients failed to alter target gene expression or clinical markers over four weeks.

Limits

The sample size was modest (89 participants across three arms) and the treatment duration was short (four weeks). The cohort was restricted to individuals able to undergo bronchoscopy, which may exclude more severe COPD phenotypes, and specific quantitative data and confidence intervals for secondary endpoints were omitted from the abstract.

Cited by